Evidence map›Paper›PMID 32101305›Full record

ArticleJAMA network open2020

Association of Leukocyte Telomere Length With Mortality Among Adult Participants in 3 Longitudinal Studies.

Konstantin G Arbeev, Simon Verhulst, Troels Steenstrup, Jeremy D Kark, Olivia Bagley, Charles Kooperberg, Alexander P Reiner, Shih-Jen Hwang, Daniel Levy, Annette L Fitzpatrick and 3 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 2 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Selenium and Coenzyme QNutrients · 2022
    Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 4 countries.

Konstantin G ArbeevBiodemography of Aging Research Unit, Social Science Research Institute, Duke University, Durham, North Carolina.
Simon VerhulstGroningen Institute for Evolutionary Life Sciences, University of Groningen, the Netherlands.
Troels SteenstrupEpidemiology, Biostatistics, and Biodemography, Institute of Public Health, University of South Denmark, Odense, Denmark.
Jeremy D KarkEpidemiology Unit, Hebrew University-Hadassah School of Public Health and Community Medicine, Jerusalem, Israel.
Olivia BagleyBiodemography of Aging Research Unit, Social Science Research Institute, Duke University, Durham, North Carolina.
Charles KooperbergDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Alexander P ReinerDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Shih-Jen HwangPopulation Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Daniel LevyPopulation Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Annette L FitzpatrickDepartment of Epidemiology, University of Washington, Seattle.
Kaare ChristensenDepartment of Clinical Genetics, Odense University Hospital, Odense, Denmark.
Anatoliy I YashinBiodemography of Aging Research Unit, Social Science Research Institute, Duke University, Durham, North Carolina.
Abraham AvivCenter of Human Development and Aging, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark.
Social Science Research Council · USFred Hutch Cancer Center · USUniversity of Southern Denmark · DKHebrew University of Jerusalem · ILNational Heart Lung and Blood Institute · USNational Institutes of Health · USRutgers, The State University of New Jersey · USUniversity of Groningen · NLUniversity of Washington · US

Funding

THE FRAMINGHAM HEART STUDYN01HC25195 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAMACHANDRAN, VASAN S · 2007 to 2014
$83.8M
Framingham Project/LevyZIAHL006001 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LEVY, DANIEL · 2009 to 2025
$51.1M
STALLARD Admin Supp: Predicting Future Care Needs and Costs for Individual Medicare Enrollees with Incident Suspected Alzheimer's DiseaseP30AG034424 · NIA · DUKE UNIVERSITY · PI SCOTT M. LYNCH · 2009 to 2026
$12.2M
Exceptional Survival: Trajectories to Functional Aging (CHS All Stars)R01AG023629 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEWMAN, ANNE B. · 2004 to 2016
$9.5M
Relationships among Genetic Regulators of Aging Health and LifespanP01AG043352 · NIA · DUKE UNIVERSITY · PI KULMINSKI, ALEXANDER M · 2014 to 2018
$8.7M
CHS research resources for the cardiovascular health of older adultsU01HL130114 · NHLBI · UNIVERSITY OF WASHINGTON · PI BURKE, GREGORY L, KRONMAL, RICHARD A · 2016 to 2019
$6.6M
CHS Events Follow-up StudyU01HL080295 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE M · 2005 to 2008
$4.6M
Determinants of Leukocyte Telomere Length at BirthR01HD071180 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AVIV, ABRAHAM, FACTOR-LITVAK, PAM R · 2012 to 2016
$3.3M
Leukocyte Telomere Length and Cardiovascular Disease in Jackson Heart StudyR01HL116446 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI AVIV, ABRAHAM, REINER, ALEXANDER P · 2013 to 2016
$3.1M
Role of EIIIA fibronectin in pulmonary fibrosisR01HL085083 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WHITE, ERIC S · 2007 to 2011
$1.9M
CHS-Transition PhaseN01HC55222 · NHLBI · PI , · 2007 to 2007
$575k
Explanations of Racial Disparities in Active LifeR03HD050374 · NICHD · PRINCETON UNIVERSITY · PI LYNCH, SCOTT M · 2005 to 2006
$156k
NHLBI NIH HHS HHSN268200800007CNHLBI NIH HHS HHSN268201200036CNHLBI NIH HHS HHSN268201600001CNHLBI NIH HHS HHSN268201600002CNHLBI NIH HHS HHSN268201600003CNHLBI NIH HHS HHSN268201600004CNHLBI NIH HHS HHSN268201600018CNHLBI NIH HHS HHSN268201800001CNHLBI NIH HHS N01HC25195NHLBI NIH HHS N01HC55222NHLBI NIH HHS N01HC85079NHLBI NIH HHS N01HC85080NHLBI NIH HHS N01HC85081NHLBI NIH HHS N01HC85082NHLBI NIH HHS N01HC85083NHLBI NIH HHS N01HC85086NHLBI NIH HHS R01 HL116446NHLBI NIH HHS U01 HL080295NHLBI NIH HHS U01 HL130114NIA NIH HHS P01 AG043352NIA NIH HHS P30 AG034424NIA NIH HHS R01 AG023629NICHD NIH HHS R01 HD071180NICHD NIH HHS R03 HD050374
6 · The paper itself

Abstract

Importance: Leukocyte telomere length (LTL) is a trait associated with risk of cardiovascular disease and cancer, the 2 major disease categories that largely define longevity in the United States. However, it remains unclear whether LTL is associated with the human life span. Objective: To examine whether LTL is associated with the life span of contemporary humans. Design, Setting, and Participants: This cohort study included 3259 adults of European ancestry from the Cardiovascular Health Study (CHS), Framingham Heart Study (FHS), and Women's Health Initiative (WHI). Leukocyte telomere length was measured in 1992 and 1997 in the CHS, from 1995 to 1998 in the FHS, and from 1993 to 1998 in the WHI. Data analysis was conducted from February 2017 to December 2019. Main Outcomes and Measures: Death and LTL, measured by Southern blots of the terminal restriction fragments, were the main outcomes. Cause of death was adjudicated by end point committees. Results: The analyzed sample included 3259 participants (2342 [71.9%] women), with a median (range) age of 69.0 (50.0-98.0) years at blood collection. The median (range) follow-up until death was 10.9 (0.2-23.0) years in CHS, 19.7 (3.4-23.0) years in FHS, and 16.6 (0.5-20.0) years in WHI. During follow-up, there were 1525 deaths (482 [31.6%] of cardiovascular disease; 373 [24.5%] of cancer, and 670 [43.9%] of other or unknown causes). Short LTL, expressed in residual LTL, was associated with increased mortality risk. Overall, the hazard ratio for all-cause mortality for a 1-kilobase decrease in LTL was 1.34 (95% CI, 1.21-1.47). This association was stronger for noncancer causes of death (cardiovascular death: hazard ratio, 1.28; 95% CI, 1.08-1.52; cancer: hazard ratio, 1.13; 95% CI, 0.93-1.36; and other causes: hazard ratio, 1.53; 95% CI, 1.32-1.77). Conclusions and Relevance: The results of this study indicate that LTL is associated with a natural life span limit in contemporary humans.

Indexed as

Life ExpectancyAgedAged, 80 and overCardiovascular DiseasesFemaleHumansLeukocytesLongitudinal StudiesMaleMiddle AgedNeoplasmsTelomere

Identifiers

PMID32101305
PMCPMC7137690
OpenAlexW3008973765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.